Presentation and applied case study of a system-wide workflow which supports rapid, systematic and efficient continuous seeded cooling crystallisation process design, with the aim to deliver a robust, consistent process with tight control of particle attributes.
1 January 2019 in International Journal of Pharmaceutics
Wet milling coupled with crystallisation has considerable potential to deliver enhanced control over particle attributes. The effect of process conditions and wet mill configuration on particle size, shape and surface energy has been investigated on acetaminophen using a seeded cooling crystallisation coupled with a wet mill unit generating size controlled acetaminophen crystals through an interchangeable rotor-tooth configuration. The integrated wet milling crystallisation platform incorporates inline focused beam reflectance measurement (FBRM) and particle vision measurement (PVM) for in-depth understanding of particle behaviour under high-shear conditions. We used a recently developed computational tool for converting chord length distribution (CLD) from FBRM to particle size distribution (PSD) to obtain quantitative insight into the effect of the competing mechanisms of size reduction and growth in a wet milling seeded crystallisation process for acetaminophen. The novelty of our wet milling crystallisation approach is in delivery of consistent surface energies across a range of particle sizes. This highlights the potential to engineer desirable particle attributes through a carefully designed, highly intensified crystallisation process.
Background/Objectives: Spherical agglomeration is a particle size enlargement technique with promise to improve micromeritic properties of active pharmaceutical ingredients. In a spherical agglomeration process, an immiscible bridging liquid is added to suspended crystals, inducing agglomeration. Interaction between primary particles and bridging liquid is essential for agglomeration to occur, and mixing is critical as it influences flow profiles and particle suspension. Benchtop-scale stirred tanks are commonly used for spherical agglomeration research. However, there is little consistency in the tank and impeller design, resulting in limited understanding of the influence mixing has on agglomerate properties. Methods: To inform spherical agglomeration reactor design, four industrial standard impeller geometries promoting differing levels of radial and axial flow in the tank were tested in a 1 L stirred tank at impeller speeds ranging from 300 rpm to 600 rpm. The impeller clearance-to-vessel diameter ratio was varied between 0.18 and 0.33 to determine the influence that impeller characteristics have on spherical agglomerates. Corresponding CFD simulations were conducted in ANSYS Fluent to understand vessel flow patterns with different impeller geometries, speeds and clearances. Results: Experimental results suggest impellers with increased power number produce more consistent agglomerates. CFD simulations showed a clear influence of impeller clearance on particle suspension and velocity profile in the tank. Conclusions: Whilst experimental studies and CFD studies have been conducted for spherical agglomeration, this work provides a systematic investigation that compares both CFD and experimental analysis for industrial standard impeller geometries to understand the important, yet underexamined link between impeller characteristics and spherical agglomerate shape and size.
4 February 2026 in International Journal of Pharmaceutics
Spherical agglomeration presents a promising particle engineering strategy for converting crystalline active pharmaceutical ingredients (APIs) with challenging bulk powder properties into manufacturable drug products. However, a critical gap remains in understanding their downstream processability via direct compression and the resulting drug release performance. This study provides a comprehensive assessment of how a successfully spherical agglomerated API, prepared at controlled particle sizes, influences tablet mechanical behaviour, microstructure arrangement, and dissolution performance. Three agglomerate size fractions (35 µm, 88 µm, and 143 µm), together with the original un-agglomerated API, were each formulated at a fixed 20% w/w drug load using an identical direct compression excipient blend (FastFlo 316, Avicel PH-101, AcDiSol, Ligamed MF-2 V) and evaluated alongside a benchmark wet granulated formulation. Compactability and compressibility modelling demonstrated systematic trends in tablet strength and densification across all formulations, with agglomerate size exerting only a minor influence on compactability. Advanced Raman imaging and nano-CT, integrated with data-driven tablet microstructure analysis, revealed that smaller agglomerates and un-agglomerated particles promoted more homogeneous API distributions, whereas larger agglomerates formed more localized clusters within the tablet matrix. Post-compression in-tablet particle and pore size distributions showed agglomerate domains were largely preserved during compaction. In-vitro dissolution studies further showed that all spherical agglomerate formulations achieved rapid drug release, meeting the label requirement of Q = 75% within 45 min, with a modest particle size dependence observed under biorelevant dissolution conditions across gastric, duodenal, and jejunal compartments. Overall, the results demonstrate that under the tested particle sizes, spherical agglomerates were suitable for direct compression solid dosage form manufacturing.